A5041465434- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Radiomics and Machine Learning in Medical Imaging
- Cancer Immunotherapy and Biomarkers
- RNA modifications and cancer
- Brain Metastases and Treatment
- Ferroptosis and cancer prognosis
- Hepatocellular Carcinoma Treatment and Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- HER2/EGFR in Cancer Research
- Cancer-related molecular mechanisms research
- Cancer therapeutics and mechanisms
- Cancer Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Peptidase Inhibition and Analysis
- PI3K/AKT/mTOR signaling in cancer
- Cancer Mechanisms and Therapy
- Advanced Breast Cancer Therapies
- Monoclonal and Polyclonal Antibodies Research
- Inflammatory Biomarkers in Disease Prognosis
Guangdong General Hospital
2012-2024
Guangdong Academy of Medical Sciences
2015-2024
Guangdong Provincial People's Hospital
2007-2024
Southern Medical University
2022-2024
First Affiliated Hospital of Anhui Medical University
2024
Anhui Medical University
2024
Lilly (China)
2022
Novartis (Germany)
2022
Novartis Institutes for BioMedical Research
2022
Novartis (Switzerland)
2022
The KUNPENG study aimed to evaluate the efficacy and safety of vebreltinib (also known as bozitinib, APL-101, PLB-1001, CBT-101), a potent highly selective inhibitor c-mesenchymal-epithelial transition (MET), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring c-Met alterations. This multicenter, multicohort, open-label, single-arm, phase II trial enrolled dysregulated, NSCLC from January 2020 August 2022 across 17 centers. Cohort 1 included MET exon...
9005 Background: ADJUVANT-CTONG1104, a randomized phase 3 trial showed adjuvant gefitinib treatment significantly improved disease-free survival (DFS) vs standard doublet chemotherapy in patients (pts) with epidermal growth factor receptor ( EGFR) mutation-positive resected stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC). 5-year rate of N1N2 were 38%-50% IASLC staging system. Here, we present the final overall (OS) results from study. Methods: From Sep 2011 to April 2014, 222...
The efficacy of crizotinib, an adenosine triphosphate–competitive, type I mesenchymal-epithelial transition (MET) inhibitor, was compromised by the development acquired secondary-site mutations such as MNNG HOS Transforming gene D1228N/H/V and Y1230H.1–4 Type II inhibitors, cabozantinib, bind to inactive conformation MET, inhibiting a broader array kinase targets.5 A limited number studies have reported MET inhibitor–associated resistance. In this study, we described patient with EGFR-mutant...
8502 Background: Median Overall survival (mOS) of stage IIIA resected NSCLC was 59.4 months (m) in CTONG 1104 adj gefitinib and 26.2m SAKK neoadjuvant chemo trial. EMERGING-CTONG1103 showed neo-adjuvant/adjuvant erlotinib treatment significantly improved progression-free (PFS) vs standard doublet chemotherapy patients (pts) with epidermal growth factor receptor ( EGFR) mutation-positive resectable (N2) non-small-cell lung cancer (NSCLC). Here, we present the final overall (OS) results from...
One Kirsten Ras (
Literatures regarding the prevalence and clinical significance of compound EGFR mutations are limited. Until now, none retrospective or prospective research has focused on in cis except case reports. In this study, we screened a cohort 3,000 treatment-naïve Chinese advanced NSCLC patients using capture-based ultra-deep targeted sequencing to evaluate efficacy EGFR-TKI population. Of screened, 1,266 (42.2%) had mutation; among them, 15 (1.2%) harboring mutations, with 10 carrying L858R...
To establish recommended phase II dose (RP2D) in I and evaluate safety efficacy of abivertinib patients with EGFR Thr790Met point mutation (T790M)-positive(+) non-small cell lung cancer (NSCLC) disease progression from prior inhibitors II.
8042 Background: Pemetrexed or gefitinib is one of the standard second-line treatments for advanced non-squamousNSCLC in East Asia. The CTONG 0806 a multi-center, randomized, controlled, open-label phase II trial was designed to explore efficacy pemetrexed versus as treatment NSCLC patients without EGFR mutation. Methods: with locally metastatic, non-squamous previously treated platinum-based chemotherapy and no mutation exons 18-21 were enrolled. Patients 1:1 randomized receive either 250...
9022 Background: Approximately 1–2% of NSCLCs harbor a rearrangement the ROS1 gene, an oncogene for which screening is difficult due to its low incidence. Crizotinib, inhibitor anaplastic lymphoma kinase (ALK), ROS1, and MET, showed marked antitumor activity in ROS1-positive advanced NSCLC (Shaw, N Engl J Med 2014). In present study, we assessed safety crizotinib East Asian pts with NSCLC. Methods: this ongoing open-label, single-arm phase II study (NCT01945021), ROS1-positive, ALK-negative...
<h3>Importance</h3> Owing to the improvement of systemic therapies for lung cancer, patients live longer, but incidence central nervous system (CNS) metastases also increases. Cerebrospinal fluid (CSF) has been proven better than plasma reveal unique genetic profiling intracranial metastases. How alterations in CSF are associated with prognosis this heterogeneous patient group remains elusive. <h3>Objective</h3> To examine association molecular survival a diagnosis adenocarcinoma and CNS...
Abstract Introduction: Cellular mesenchymal-epithelial transition (cMET) dysregulation has been described in non-small-cell lung cancer (NSCLC) and implicated as a negative prognostic factor. It can occur amplification, overexpression or mutations leading to exon 14 skipping. Bozitinib (PLB-1001, CBT-101) is potent highly selective cMET inhibitor, which demonstrated superior activity both vitro vivo NSCLC models. Methods: This was phase I, open-label multicenter study conducted locally...
Metabolism reprogramming within the tumor microenvironment (TME) can have a profound impact on immune cells. Identifying association between metabolic phenotypes and cells in lung adenocarcinoma (LUAD) may reveal mechanisms of resistance to checkpoint inhibitors (ICIs). Metabolic were classified by expression genes. Somatic mutations transcriptomic features compared across different phenotypes. The phenotype LUAD is predominantly determined reductase-oxidative activity divided into two...
9022 Background: In current clinical setting, NSCLC patients harboring specific driver mutation were usually treated guiding by prior profiling of the primary tumor when developed to brain metastasis. Some studies have shown that circulating DNA (ctDNA) derived from cerebrospinal fluid (CSF) can reveal unique genomic alterations present in malignancies. We assessed CSF as a liquid biopsy media and compared matched plasma. Methods: performed capture-based ultra deep sequencing on ctDNA CSF,...
Despite the reported efficacy of osimertinib, central nervous system (CNS) progression is still frequent in EGFR-mutated NSCLC. This study aimed to reveal site-specific resistant mechanisms osimertinib and investigate subsequent treatments for leptomeningeal metastases (LM).EGFR-mutated NSCLC with LM who progressed on were included. Molecular analysis cerebrospinal fluid (CSF) at was performed. Subsequent collected analyzed.A total 246 patients identified. Only those as a site included...